ONC

#405
BeOne Medicines Ltd. American Depositary Shares
305.6400 USD
-1.30%
Settore:
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
305.6400
305.6400
Intervallo Annuale
271.4701
385.2200
Variazione giornaliera
-1.30%
Variazione Mensile
+6.83%
Variazione di 6 mesi
-3.19%
Variazione Annuale
-3.19%
Chiusura Precedente
309.6600
Apertura
305.6400
Bid
Ask
Minimo
305.6400
High
305.6400
Volume
74
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 33.9086 B
  • Employee 12 K
  • Founded 2010
  • CEO John Vincent OylerJohn Vincent Oyler
  • Website www.beonemedicines.com
  • Headquarter N/A
  • FIGI BBG00B6WF7T5
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
1 599
Rapporto prezzo/fatturato
83.86

BeOne Medicines Ltd - American Depositary Shares

BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market. BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025.